A share price of Corvus Pharmaceuticals Inc [CRVS] is currently trading at $7.11, up 2.60%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CRVS shares have gain 1.86% over the last week, with a monthly amount glided 21.96%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Corvus Pharmaceuticals Inc [NASDAQ: CRVS] stock has seen the most recent analyst activity on October 13, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $16. Previously, H.C. Wainwright started tracking the stock with Buy rating on January 02, 2025, and set its price target to $11. On August 18, 2023, Oppenheimer initiated with a Outperform rating and assigned a price target of $7 on the stock. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $10 as its price target on May 27, 2021. Mizuho downgraded its rating to Neutral for this stock on February 10, 2021, and downed its price target to $4. In a note dated September 12, 2019, Mizuho initiated an Buy rating.
Corvus Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $2.54 and $10.00. Currently, Wall Street analysts expect the stock to reach $13.5 within the next 12 months. Corvus Pharmaceuticals Inc [NASDAQ: CRVS] shares were valued at $7.11 at the most recent close of the market. An investor can expect a potential return of 89.87% based on the average CRVS price forecast.
Analyzing the CRVS fundamentals
Gross Profit Margin for this corporation currently stands at -0.31% with Operating Profit Margin at -403.89%, Pretax Profit Margin comes in at -512.9%, and Net Profit Margin reading is -512.9%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -1.03 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Corvus Pharmaceuticals Inc [NASDAQ:CRVS] is 8.91. Also, the Quick Ratio is 8.91, while the Cash Ratio stands at 1.73.
Transactions by insiders
Recent insider trading involved ORBIMED ADVISORS LLC, Director, that happened on Jun 27 ’25 when 1.18 million shares were sold. Director, Thompson Peter A. completed a deal on Jun 27 ’25 to sell 1.18 million shares.
